EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice

Dandan Wei, Dan Huang, Shufen Wang, Wenyu Li, Hongdi Xiong, Sijian Wen

Dermatology · 07.08.2025 · 1-6

DOI: 10.1159/000547786 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, online erschienen am 07.08.2025. Verfasst von Dandan Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Alopecia Areata, Purines, Azetidines, Sulfonamides. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Alopecia areata (AA) is an autoimmune disorder with a higher prevalence in pediatric patients than adults, but treatment options remain limited. Baricitinib, a Janus kinase (JAK)-1/2 inhibitor, has shown efficacy in adults with severe AA, yet data on its use in pediatric patients are limited.

Methods

This study included pediatric patients (ages 2–18) with severe AA (Severity of Alopecia Tool [SALT] ≥50) treated with baricitinib for at least 3 months between January 2023 and October 2024. Demographics, SALT scores before and after treatment, and adverse events were collected.

Results

Thirty-three patients were included, with a mean age of 9.93 years and average disease duration of 23.44 months. Sixteen patients received 2 mg and 17 received 4 mg of baricitinib. At baseline, 54.5% had a SALT score above 90. After treatment, 45.5% of patients had a 50% reduction in their SALT score. The average treatment duration was 6.5 months. Adverse events included elevated ALT (n = 1), acne (n = 1), and upper respiratory infection (n = 1), with no serious adverse events.

Conclusion

Baricitinib demonstrated clinical efficacy and good tolerance in pediatric patients with severe AA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataPurinesAzetidinesSulfonamidesPyrazolesJanus Kinase InhibitorsHumansChildMaleFemaleAdolescentChild, PreschoolTreatment OutcomeSeverity of Illness IndexRetrospective Studies

Stichwörter der Autor:innen

Alopecia areataBaricitinibEfficacyPediatric patientsSafety

Substanzen

baricitinibPurinesAzetidinesSulfonamidesPyrazolesJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Dermatology and Venereology, Wuming Affiliated Hospital of Guangxi Medical University, Nanning, China.
  • Department of Dermatology and Venereology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China, wensijian1018@163.com.

Zitieren

APA

Wei, D., Huang, D., Wang, S., Li, W., Xiong, H., & Wen, S. (2025). Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice. Dermatology, 1-6. https://doi.org/10.1159/000547786

Vancouver

Wei D, Huang D, Wang S, Li W, Xiong H, Wen S. Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice. Dermatology. 2025:1-6. doi:10.1159/000547786

BibTeX
@article{Wei2025,
  author = {Wei, Dandan and Huang, Dan and Wang, Shufen and Li, Wenyu and Xiong, Hongdi and Wen, Sijian},
  title = {Efficacy and Safety of Baricitinib in the Treatment of Severe Alopecia Areata in Pediatric Patients: Data from Real-Clinical Practice},
  journal = {Dermatology},
  year = {2025},
  pages = {1--6},
  doi = {10.1159/000547786}
}
Kostenlos starten →